Asset Details
Do you wish to reserve the book?
ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
Do you wish to request the book?
ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
2025
Overview
Gastric cancer (GC) is characterised by a dense stromal microenvironment, lack of therapeutic targets, and limited effective treatment options, collectively leading to a poor prognosis. Here, we identify UL16 binding protein 2 (ULBP2) as a potential therapeutic target in GC. Mechanistically, ULBP2 overexpression activates the TGF-β signalling pathway, promoting the activation of cancer-associated fibroblasts (CAFs) and tumor progression in GC. Furthermore, we developed ULBP2 CAR-T cells and assessed their therapeutic potential in GC cell lines, organoids, cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. We showed that ULBP2 CAR-T cells effectively eliminated GC cell lines and organoids and, either alone or in combination with an anti-PD-1 antibody, significantly inhibited tumor growth and prolonged survival in both CDX and PDX mouse models. In conclusion, ULBP2 contributes to GC progression by promoting TGF-β mediated CAF activation, which collectively reinforce the dense stromal microenvironment. Targeting ULBP2 suppresses tumor growth, reduces stromal deposition, and promotes T cell infiltration, thereby enhancing the efficacy of immunotherapy in GC.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ 13/105
/ 13/109
/ 13/31
/ 13/44
/ 13/51
/ 14/19
/ 59/5
/ 64/60
/ Animals
/ Biomedical and Life Sciences
/ Cancer-Associated Fibroblasts - immunology
/ Cancer-Associated Fibroblasts - metabolism
/ Cancer-Associated Fibroblasts - pathology
/ Collagen
/ Female
/ Genes
/ Humans
/ Mice
/ Ontology
/ Patients
/ Stomach Neoplasms - immunology
/ Stomach Neoplasms - pathology
/ Transforming Growth Factor beta - metabolism
/ Transforming growth factor-b
/ Tumors
